IP Library Granted Patent US 8,834,487
Granted Patent B2
US 8,834,487 · App. 12/842,775 · Granted Sep 16, 2014

Systems and methods for preventing intravasation during intrauterine procedures

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,834,487
App. No.
12/842,775
Granted
Sep 16, 2014
Kind
B2
Abstract

Systems, methods, apparatus and devices for performing improved gynecologic and urologic procedures are disclosed. Patient benefit is achieved through improved outcomes, reduced pain, especially peri-procedural pain, and reduced recovery times. The various embodiments enable procedures to be performed outside the hospital setting, such as in a doctor's office or clinic. Distension is achieved mechanically, rather than with liquid distension media, thereby eliminating the risk of intravasation.

Claims (27)

1. An intravasation prevention system for use during an intrauterine procedure, comprising:

an elongate flexible tubular sheath configured for transcervically accessing a uterus, the sheath having a proximal end, a distal end, a lumen extending therethrough, and an outside diameter of no more than about 9 mm;

a mechanical distension device having an expanded state and a collapsed state, wherein the distension device comprises an expandable basket device configured for insertion through the lumen of the elongate flexible tubular sheath and into the uterus while in the collapsed state, and configured to distend the uterus to expose a site therein when in the expanded state;

a visualization device configured for visualizing the site exposed by the distension device, and

a surgical tool configured for accessing the site and for performing a procedure at the site while the mechanical distension device is in the expanded state,

wherein the surgical tool is a morcellator configured to remove a uterine fibroid from the site.

2. The intravasation prevention system of claim 1 , further comprising a guidewire, wherein the elongate flexible tubular sheath is configured to transcervically access the uterus by advancing the elongate flexible tubular sheath over the guidewire.

3. The intravasation prevention system of claim 1 , wherein the mechanical distension device is configured to achieve an equivalent distension to that achieved by introduction of a liquid distension media at a pressure of at least 40 mm Hg.

4. The intravasation prevention system of claim 1 , wherein the mechanical distension device is configured to achieve an equivalent distension to that achieved by introduction of a liquid distension media at a pressure of about 70 mm Hg.

5. The intravasation prevention system of claim 1 , further comprising a dilation apparatus configured to dilate a cervix prior to transcervically accessing the uterus with the elongate flexible tubular sheath.

6. The intravasation prevention system of claim 1 , wherein the expandable basket device comprises a scaffolding having filaments.

7. The intravasation prevention system of claim 6 , wherein the site at which the procedure is performed comprises tissue positioned between the filaments when the mechanical distension device is in the expanded state.

8. An intravasation prevention system for use during an intrauterine procedure, comprising:

an elongate tubular sheath configured for transcervically accessing a uterus, the sheath having a proximal end, a distal end, and a lumen extending therethrough;

a mechanical distension device having an expanded state and a collapsed state, wherein the distension device comprises an expandable basket device configured for insertion through the lumen of the elongate tubular sheath and into the uterus while in the collapsed state, and configured to distend the uterus and expose a site therein while in the expanded state; and

a surgical tool configured for accessing the site and for performing a procedure at the site while the mechanical distension device is in the expanded state, wherein the surgical tool is a morcellator configured to remove a uterine fibroid from the site.

9. The intravasation prevention system of claim 8 , further comprising a guidewire, wherein the elongate tubular sheath is configured to transcervically access the uterus by advancing the elongate tubular sheath over the guidewire.

10. The intravasation prevention system of claim 8 , wherein the mechanical distension device is configured to achieve an equivalent distension to that achieved by introduction of a liquid distension media at a pressure of at least 40 mm Hg.

11. The intravasation prevention system of claim 8 , wherein the mechanical distension device is configured to achieve an equivalent distension to that achieved by introduction of a liquid distension media at a pressure of about 70 mm Hg.

12. The intravasation prevention system of claim 8 , further comprising a dilation apparatus configured to dilate a cervix prior to transcervically accessing the uterus with the elongate tubular sheath.

13. The intravasation prevention system of claim 8 , wherein the expandable basket device comprises a scaffolding having filaments.

14. The intravasation prevention system of claim 13 , wherein the site at which the procedure is performed comprises tissue positioned between the filaments when the mechanical distension device is in the expanded state.

15. An intravasation prevention system for use during an intrauterine procedure, comprising:

an elongate tubular sheath configured for transcervically accessing a uterus, the sheath having a proximal end, a distal end, and a lumen extending therethrough;

a mechanical distension device comprising an inflatable device having an inflated state and a deflated state, wherein the inflatable device is configured for insertion through the lumen of the elongate tubular sheath and into the uterus while in the deflated state, and configured to distend the uterus and expose a site therein while in the inflated state; and

a surgical tool configured for accessing the site and for performing a procedure at the site while the inflatable device is in the inflated state,

wherein the surgical tool is a morcellator configured to remove a uterine fibroid from the site.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2011
From: INTERLACE MEDICAL, INC.
To: HOLOGIC, INC.
Reel/Frame 025835/0684 →